FRIEDMAN PAUL A
SEC Form 4 insider trading activity
FRIEDMAN PAUL A has filed 5 SEC Form 4 filings (73 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jan 13, 2026.
On the most recent filing, FRIEDMAN PAUL A is listed as Director at MADRIGAL PHARMACEUTICALS, INC. Inside the rolling window, FRIEDMAN PAUL A reported no open-market purchases and 2 open-market sales totaling $26.7M in MDGL. The largest disclosed transaction in the window is a sale of 24,800 MDGL shares on Dec 10, 2025, worth $13.7M.
Companies traded
Other insiders at MDGL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$26.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has FRIEDMAN PAUL A made?
FRIEDMAN PAUL A has filed 5 SEC Form 4 filings (73 transaction rows) across 1 company since 2025.
Which companies does FRIEDMAN PAUL A trade?
FRIEDMAN PAUL A has filed SEC Form 4 disclosures for 1 company, including MDGL.
When was FRIEDMAN PAUL A's most recent SEC Form 4 filing?
FRIEDMAN PAUL A's most recent SEC Form 4 filing on Tracefour is dated Jan 13, 2026.
What is FRIEDMAN PAUL A's total buy and sell value in the current window?
Inside the rolling retention window, FRIEDMAN PAUL A bought $0 and sold $26.7M based on SEC Form 4 filings.
What was FRIEDMAN PAUL A's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 24,800 MDGL shares on 2025-12-10, worth $13.7M, per SEC Form 4 filings.